那他珠单抗、芬戈莫德与注射疗法在儿童期起病多发性硬化中的比较有效性:一项基于登记的研究
这项回顾性登记研究纳入1218例儿童期起病多发性硬化患者,比较那他珠单抗、芬戈莫德与注射疗法。芬戈莫德较注射疗法显著降低复发风险(HR 0.49),那他珠单抗较注射疗法(HR 0.15)和芬戈莫德(HR 0.37)均显著降低复发风险。
要点
- 芬戈莫德较注射疗法显著降低儿童期起病多发性硬化复发风险(HR 0.49)。
- 那他珠单抗较注射疗法显著降低复发风险(HR 0.15)。
- 那他珠单抗较芬戈莫德显著降低复发风险(HR 0.37)。
核心结论
- 那他珠单抗在控制儿童期起病多发性硬化复发方面比芬戈莫德更有效,芬戈莫德和那他珠单抗均比一线注射疗法更有效。
研究设计与样本
- 回顾性研究,纳入2006年1月1日至2021年5月3日期间启动注射疗法、那他珠单抗或芬戈莫德的儿童期起病多发性硬化患者,共1218例,采用逆概率治疗加权匹配。
主要发现
- 芬戈莫德组较注射疗法组复发风险显著降低(HR 0.49;95%CI 0.29-0.83;p=0.008)。
- 未匹配样本中调整既往DMT经验后,那他珠单抗组较注射疗法组复发风险显著降低(HR 0.15;95%CI 0.07-0.31;p<0.001)。
- 未匹配样本中调整既往DMT经验后,那他珠单抗组较芬戈莫德组复发风险显著降低(HR 0.37;95%CI 0.14-1.00;p=0.049)。
- 调整后的次要研究结局与主要结局或既往观察结果基本一致。
- 逆概率治疗加权调整人群中的发现经多项敏感性分析证实。
关键数值与推荐
- 主要结局为从索引治疗启动至首次复发的时间。
- 次要结局包括年化复发率、1年、2年和5年无复发患者比例、至治疗中断时间、至24周确认残疾恶化和确认残疾改善的时间。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Patients with pediatric-onset multiple sclerosis (POMS) typically experience higher levels of inflammation with more frequent relapses, and though patients with POMS usually recover from relapses better than adults, patients with POMS reach irreversible disability at a younger age than adult-onset patients. There have been few randomized, placebo-controlled clinical trials of multiple sclerosis (MS) disease-modifying therapies (DMTs) in patients with POMS, and most available data are based on observational studies of off-label use of DMTs approved for adults. We assessed the effectiveness of natalizumab compared with fingolimod using injectable platform therapies as a reference in pediatric patients in the global MSBase registry. METHODS: This retrospective study included patients with POMS who initiated treatment with an injectable DMT, natalizumab, or fingolimod between January 1, 2006, and May 3, 2021. Patients were matched using inverse probability treatment weighting. The primary outcome was time to first relapse from index therapy initiation. Secondary study outcomes included annualized relapse rate; proportions of relapse-free patients at 1, 2, and 5 years; time to treatment discontinuation; and times to 24-week confirmed disability worsening and confirmed disability improvement. RESULTS: A total of 1,218 patients with POMS were included in this analysis. Patients treated with fingolimod had a significantly lower risk of relapse than patients treated with injectable DMTs (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.29-0.83; p = 0.008). After adjustment for prior DMT experience in the unmatched sample, patients treated with natalizumab had a significantly lower risk of relapse than patients treated either with injectable DMTs (HR, 0.15; 95% CI 0.07-0.31; p < 0.001) or fingolimod (HR, 0.37; 95% CI 0.14-1.00; p = 0.049). The adjusted secondary study outcomes were generally consistent with the primary outcome or with previous observations. The findings in the inverse probability treatment weighting-adjusted patient populations were confirmed in multiple sensitivity analyses. DISCUSSION: Our analyses of relapse risk suggest that natalizumab is more effective than fingolimod in the control of relapses in this population with high rates of new inflammatory activity, consistent with previous studies of natalizumab and fingolimod in adult-onset patients and POMS. In addition, both fingolimod and natalizumab were more effective than first-line injectable therapies. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that patients with POMS treated with natalizumab had a lower risk of relapse than those with fingolimod.
引用
- Spelman T, Simoneau G, Hyde R, et al. Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study. Neurology. 2024. PMID: 38447093. doi:10.1212/WNL.0000000000208114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。